Theriva Biologics Inc

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-Appointment expected to aid advancement of Theriva's discovery program and strengthen collaboration with the Institut Catala d'Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)-

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma –

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide a corporate update.

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) - - Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) -

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma –

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Conference call to be held on Thursday, March 30 at 8:30 a.m. ET

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 27, 2023, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide a corporate update.

Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

- Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR -

Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the the B. Riley Securities 3rd Annual Oncology Conference, to be held virtually from January 18-19, 2023.

Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference

-Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA) and Spanish Agency for Medicines and Health Products (AEMPS)-

Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

-Clinical trial is being conducted at St. James's University Hospital, United Kingdom, in collaboration with the University of Leeds-

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will participate in the following upcoming investor conferences in December.

Theriva Biologics to Participate in Upcoming Investor Conferences

Theriva Biologics (NYSE:TOVX ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive and Chief Financial Officer Manel Cascalló - General Director, Theriva Biologics Europe Frank Tufaro - Chief Operating Officer Vince Wacher - Head, Corporate and Product Development Conference Call Participants Jim Molloy - Alliance Global Partners Operator Good day and welcome to the Theriva Biologics formerly Synthetic Biologics 2022 Third Quarter Operational Highlights and Financial Results. Today's conference is being recorded.

Theriva Biologics (TOVX) Q3 2022 Earnings Call Transcript

–Reported encouraging clinical data supporting the differentiated mode-of action of Theriva's novel oncolytic adenovirus (OV) platform–

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

-Conference call to be held on Friday, November 11 at 8:30 a.m. ET-

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, November 10, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update.

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

- Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee -

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

-Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET- -Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET-

Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics

- Data to be featured in an oral presentation highlighting the encouraging biological activity of VCN-01 treatment in combination with durvalumab- - Data to be featured in an oral presentation highlighting the encouraging biological activity of VCN-01 treatment in combination with durvalumab-

Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics

Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration

News for Theriva Biologics Inc Stock (TOVX)